PTGER4 and urinary bladder carcinoma: The TPST-1495 dual EP2 and EP4 antagonist is in phase 1a/1b as single treatment or in association with pembrolizumab in solid tumors (bladder cancer, triple negative breast cancer, gastric cancer) (NCT04344795 clinicaltrials.gov).